Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07416604 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Study acronym: ZEBRHA 2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 42 → 59 locations Eligibility criteria expanded, about 11 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 11 words
  2. Trial sites expanded: 30 → 42 locationsv8
  3. Trial sites expanded: 12 → 30 locationsv7
  4. Trial sites expanded: 8 → 12 locationsv6
  5. Study sites: 6 to 8v5
  6. Trial sites expanded: 3 → 6 locations Start date changed from estimate of Apr 30, 2026 to Apr 27, 2026v4 Show 1 more changeShow less
    • Start date changed from estimate of Apr 30, 2026 to Apr 27, 2026
  7. Recruitment opened Trial sites expanded: 0 → 3 locationsv3 Show 1 more changeShow less
    • Trial sites expanded: 0 → 3 locations
  8. Re-verified, no change to tracked fieldsv2
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
Hemophilia
236 trials monitored
See 12 trials at risk
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.
Trial Details
NCT Number NCT07416604
Lead Sponsor Hoffmann-La Roche
Collaborators: Chugai Pharmaceutical
Conditions Hemophilia A
Enrollment 360 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov